NCT06446154View on ClinicalTrials.gov

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

July 1, 2026

Conditions
Hepatocellular CarcinomaImmune Checkpoint InhibitorsAnti-angiogenic TherapySecond-line Treatment
Interventions
DRUG

Fruquintinib

Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen university cancer center, Guangzhou

All Listed Sponsors
collaborator

Guangzhou First People's Hospital

OTHER

lead

Sun Yat-sen University

OTHER